Drug Trial Radar · NCT00362856
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
Last checked: Nov 19, 2026Latest source record: Sep 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Sep 13, 2006
Primary completion
Mar 6, 2007
Study completion Mar 6, 2007
Sponsor
- Lead sponsor
- 9 Meters Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was run to determine the safety, tolerance, and efficacy of multiple doses of larazotide acetate in subjects with celiac disease following a gluten challenge.
Conditions
- Celiac Disease
Interventions
larazotide acetateDrug
capsule
PlaceboDrug
capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the safety and tolerability of multiple, oral doses of larazotide acetate in celiac disease subjects that maintain a gluten-free diet.Time frame: Safety measurements were performed at Screening and at Day 0, 7, 14, and 21 ('End of Study'). Any change from baseline value was calculated at each subsequent visit until "End of Study" (Day 21).
- To evaluate the efficacy of multiple dose levels of larazotide acetate in preventing intestinal permeability changes induced by gluten challengeTime frame: On Days 0, 6, 13, and 20 subjects drank a solution of lactulose and mannitol. Subject's urine was collected during the day on Day 0 and overnight prior to subsequent visits and analyzed for LAMA recoveries via standardized methodologies.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Scottsdale, Arizona
Site not named
San Diego, California
Research Site
Boston, Massachusetts
Research Site
Rochester, Minnesota
Site not named
Morristown, New Jersey
Site not named
Bismarck, North Dakota
Research Site
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Research Site
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.